Revance raises $25 million for topical botulinum product
05 January 2010
Simon Varcoe
Please Login to read the full article.
05 January 2010
Simon Varcoe
simon.varcoe@informa.com
Revance Therapeutics, a private biopharmaceutical company, has raised $25 million in the first closing of a $35 million series D financing round.
Revance is focused on applying its TransMTS platform technology to deliver targeted large macromolecules across the skin. Its lead product, RT001,...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
